TARRYTOWN, N.Y.--(BUSINESS WIRE)--PsychoGenics Inc. today announced positive data from its randomized, placebo controlled, multicenter, Phase IIa trial of eltoprazine, the company’s lead partial 5-HT1A – 5-HT1B receptor agonist, in adult patients with Attention Deficit/ Hyperactivity Disorder (ADHD). The primary objective of the exploratory study was to compare the effects of two doses of eltoprazine with placebo in a cross-over design on the symptoms of ADHD in adults using the total scores from the ADHD Rating Scale-Version IV.
